Scotiabank Issues Positive Forecast for Twist Bioscience (NASDAQ:TWST) Stock Price

Twist Bioscience (NASDAQ:TWST) had its target price lifted by Scotiabank from $54.00 to $62.00 in a research note released on Tuesday morning,Benzinga reports. The firm currently has a sector outperform rating on the stock.

A number of other analysts also recently issued reports on TWST. Robert W. Baird lifted their price target on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday. Barclays dropped their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Wolfe Research assumed coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. TD Cowen reaffirmed a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Finally, Leerink Partners increased their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and a consensus price target of $53.80.

Twist Bioscience Trading Down 1.4 %

TWST stock opened at $52.02 on Tuesday. The firm has a 50 day moving average of $48.63 and a 200-day moving average of $46.21. The firm has a market capitalization of $3.09 billion, a P/E ratio of -14.45 and a beta of 1.87. Twist Bioscience has a 12 month low of $27.41 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The firm had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter in the prior year, the firm posted ($0.75) earnings per share. The business’s quarterly revenue was up 24.1% on a year-over-year basis. Sell-side analysts predict that Twist Bioscience will post -2.27 EPS for the current year.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 7,968 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $382,464.00. Following the sale, the chief executive officer now directly owns 581,584 shares of the company’s stock, valued at $27,916,032. This trade represents a 1.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Dennis Cho sold 1,507 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $72,336.00. Following the transaction, the insider now directly owns 91,163 shares of the company’s stock, valued at $4,375,824. The trade was a 1.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 48,707 shares of company stock worth $2,343,623 in the last ninety days. 3.01% of the stock is owned by company insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently made changes to their positions in TWST. AQR Capital Management LLC lifted its stake in Twist Bioscience by 83.9% in the second quarter. AQR Capital Management LLC now owns 61,428 shares of the company’s stock worth $3,027,000 after acquiring an additional 28,027 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Twist Bioscience by 3.7% during the second quarter. The Manufacturers Life Insurance Company now owns 31,064 shares of the company’s stock valued at $1,531,000 after buying an additional 1,104 shares during the period. SG Americas Securities LLC raised its stake in Twist Bioscience by 407.1% in the third quarter. SG Americas Securities LLC now owns 10,958 shares of the company’s stock worth $495,000 after buying an additional 8,797 shares in the last quarter. CWM LLC raised its stake in Twist Bioscience by 141.9% in the third quarter. CWM LLC now owns 5,894 shares of the company’s stock worth $266,000 after buying an additional 3,457 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its holdings in Twist Bioscience by 30.1% in the third quarter. Exchange Traded Concepts LLC now owns 20,141 shares of the company’s stock worth $910,000 after buying an additional 4,661 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.